TRVI
NASDAQ HealthcareTrevi Therapeutics, Inc. - Common Stock
Biotechnology
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
๐ Market Data
| Price | $13.87 |
|---|---|
| Volume | 1,101,930 |
| Market Cap | 1.97B |
| Beta | 1.000 |
| RSI (14-Day) | 55.8 |
| 200-Day MA | $10.68 |
| 50-Day MA | $12.53 |
| 52-Week High | $16.12 |
| 52-Week Low | $5.38 |
| Forward P/E | -24.55 |
| Price / Book | 9.71 |
๐ฏ Investment Strategy Scores
TRVI scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (55/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ช Falling Knife (23/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find TRVI in your text
Paste any article, transcript, or post โ the tool will extract TRVI and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.